Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 07/29 10:00:44 pm
74.81 USD   +0.20%
07/29 ARRAY BIOPHARMA : appoints Haddock as CFO
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
07/28DJBRISTOL MYERS S : -Myers Results Boosted by Cancer Drugs -- Update
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2012 | 05:26am CEST
   By Rumman Ahmed 
 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at rumman.ahmed@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
07/29 ARRAY BIOPHARMA : appoints Haddock as CFO
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
07/28 BRISTOL MYERS SQUIBB : Announces Regulatory Updates for Opdivo nivolumab in Prev..
07/28 BRISTOL MYERS SQUIBB : Patent Issued for Methods for the Preparation of HIV Atta..
07/28DJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs -- Update
07/28 BRISTOL MYERS SQUIBB : Announces Availability of FDA-Approved ORENCIA® abatacept..
07/28 BRISTOL MYERS SQUIBB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
07/28 BRISTOL MYERS SQUIBB CO : Results of Operations and Financial Condition, Financi..
07/28DJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs
07/28 BRISTOL MYERS SQUIBB : -Myers beats Street 2Q forecasts
More news
Sector news : Pharmaceuticals - NEC
08:48aDJMERCK : Earnings Watch -- WSJ
01:14a BAYER : says will halt future U.S. sales of insecticide
07/29DJTech Stocks Up On Google Earnings - Tech Roundup
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/28 Bristol-Myers Squibb (BMY) Giovanni Caforio on Q2 2016 Results - Earnings Cal..
07/28 Bristol-Myers Q2 top line up 17%; Opdivo sales up 589%; non-GAAP net income u..
07/28 Gilead Lives And Dies By Hep C
07/28 Bristol-Myers Squibb beats by $0.02, beats on revenue
07/27 Notable earnings before Thursday?s open
Advertisement
Financials ($)
Sales 2016 18 831 M
EBIT 2016 4 956 M
Net income 2016 4 376 M
Debt 2016 1 201 M
Yield 2016 2,07%
P/E ratio 2016 29,02
P/E ratio 2017 23,84
EV / Sales 2016 6,70x
EV / Sales 2017 5,89x
Capitalization 124 997 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 77,5 $
Spread / Average Target 3,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..8.75%124 997
JOHNSON & JOHNSON21.91%344 463
PFIZER INC.14.28%223 732
ROCHE HOLDING LTD.-9.99%218 231
NOVARTIS AG-5.30%215 109
MERCK & CO., INC.11.06%162 372
More Results